Perception of dry powder inhalers by asthma patients Original article
Article Sidebar
Published:
Apr 7, 2023
Keywords:
asthma, adults, perception of dry powder inhaler, Airmaster
Main Article Content
Abstract
The aim of the study was to assess the perception of dry powder inhalers by patients with asthma. A survey was conducted in a group of 98 adult patients treated with inhaled glucocorticosteroid and long-acting β2-agonist with dry powder inhalers. According to patients, the inhaler should be easy to use properly, maintain its hygiene and carry with you, have a dose counter and the availability of all drugs needed by the patient in a given inhaler. The functional and inhalation features of the Airmaster® inhaler were very well perceived by the vast majority of patients.
Downloads
Download data is not yet available.
Article Details
How to Cite
Emeryk, A., Czerwińska-Pawluk, I., Emeryk-Maksymiuk, J., & Panas, K. (2023). Perception of dry powder inhalers by asthma patients. Alergoprofil, 19(1), 3-9. https://doi.org/10.24292/01.AP.191050423
Issue
Section
THERAPY
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Emeryk A, Pirożyński M, Mazurek H (ed). Polski przewodnik inhalacyjny. 2nd ed. Via Medica, Gdańsk 2021: 1-37.
2. Mohan AR, Wang Q, Dhapare S et al. Advancements in the design and development of dry powder inhalers and potential implications for generic development. Pharmaceutics. 2022; 14(11): 2495.
3. Taki M, Ahmed S, Marriott C et al. The ‘stage-by-stage’ deposition of drugs from commercial single-active and combination dry powder inhaler formulations. Eur J Pharma Sci. 2011; 43: 225-35.
4. Chrystyn H, van der Palen J, Sharma R et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017; 27: 22.
5. De Boer AH, Hagedoorn P, Hoppentocht M et al. Dry powder inhalation: past, present and future. Exp Opin Drug Deliv. 2017; 14(4): 499-512.
6. Emeryk A, Emeryk-Maksymiuk J, Janeczek K et al. Inhalatory suchego proszku w dobie pandemii COVID-19 – co jest ważne dla pacjenta? Alergoprofil. 2021; 17(2): 3-9.
7. Emeryk A, Pirożyński M, Emeryk-Maksymiuk J. Dry powder inhalers – between the doctor and the patient. Adv Respir Med. 2018; 86(1): 44-52.
8. Sanders MJ. Guiding Inspiratory Flow: Development of the In-Check DIAL G16, a tool for improving inhaler technique. Pulm Med. 2017; 2017: 1495867.
9. Dal Negro WR, Turco P, Povero M. Patients’ usability of seven most used dry-powder inhalers in COPD. Multidiscip Respir Med. 2019; 14: 30.
10. Ciciliani AM, Langguth P, Wachtel P. Handling forces for the use of different inhaler devices. Int J Pharm. 2019; 560: 315-21.
11. Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019; 15: 461-72.
12. Global Strategy for Asthma Management and Prevention (GINA). Updated 2021.
13. Produkt DUEXON PRO f. Adamed Pharma S.A. Ulotka.
14. Patient decision aid inhalers for asthma. Information to help people with asthma and their healthcare professionals discuss their options for inhaler devices. NICE 2020 (access: 20.05.2022).
15. Panaszek B, Emeryk A, Bogacka E et al. Czynniki decydujące o akceptacji inhalatora suchego proszku przez chorych leczonych z powodu astmy lub POChP. Fam Med Prim. 2006; 8(3): 729-34.
16. Ninane V, Vandevoorde J, Cataldo D et al. New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences. Respir Med. 2015; 109(11): 1430-8.
17. Global Strategy for Prevention, Diagnosis and Management of COPD: 2023 Report (access: 10.01.2023).
18. Emeryk A, Janeczek K. Inhalatory suchego proszku np. G7 – najbardziej popularne inhalatory indywidualne. Alergia. 2020; 1: 11-3.
19. Dane firmy Adamed Pharma S.A. WELLNEX GmbH. Fluticasone Propionate/Salmeterol Inhalation Powder, Pre-dispensed 100/50 μg, 250/50 μg (Fluticasone propionate, Salmeterol xinafoate) Drug Product 3.2.P.2 Pharmaceutical Development.
20. Janeczek K, Emeryk A. Porównanie preparatów propionianu flutykazonu z salmeterolem dostępnych w inhalatorach dyskopodobnych oraz Dysku (doniesienie wstępne). Terapia. 2022; 8(415): 20-8.
21. Jones TL, Neville DM, Chauhan AJ. The Ellipta® in asthma and chronic obstructive pulmonary disease: device characteristics and patient acceptability. Ther Deliv. 2018; 9(3): 169-76.
22. Levy ML, Carroll W, Izquierdo Alonso JL et al. Understanding dry powder inhalers: key technical and patient preference attributes. Adv Ther. 2019; 36(10): 2547-57.
23. D’Urzo A, Chapman KR, Donohue JF et al. inhaler devices for delivery of LABA/LAMA fixed dose combinations in patients with COPD. Pulm Ther. 2019; 5: 23-41.
24. Ginera J, Cerrillob MV, Sierrab JA. Assessment of inhalation errors, training time and patient preference for DuoResp® Spiromax® and Symbicort® Turbuhaler® in patients with asthma and COPD. Eur Clin Respir J. 2020; 8: 1833411.
25. Krok E. Budowa kwestionariusza ankietowego a wyniki badań. Studia Informatica. Zeszyty Naukowe Uniwersytetu Szczecińskiego. 2015; 35: 55-73.
26. Serra-Batlles J, Plaza V, Radiola C et al. Patient perception and acceptability of multidose dry powder inhalers: a randomized crossover comparison of Diskus/Accuhaler with Turbuhaler. J Aerosol Med. 2002; 15: 59-64.
27. Van der Palen J, Klein JJ, Schildkamp AM. Comparison of a new multidose powder inhaler (Discus/Accuhaler) and the Turbuhaler regarding preference and ease of use. J Asthma. 1998; 35: 147-52.
28. Luyt D, Vermeulen J, Johanson L et al. A comparison of the ease of handling of the Diskus/Accuhaler inhaler and the Turbuhaler inhaler in children aged 6–12 years with asthma. J Aerosol Med. 1995; 8: 105-9.
29. Schlaeppi M, Edwards K, Fuller RW et al. Patient perception of the Diskus inhaler: a comparison with the Turbuhaler inhaler. Br J Clin Pract. 1996; 50: 14-9.
30. Emeryk A, Czerwińska I, Bartkowiak-Emeryk M. Jakie cechy inhalatora suchego proszku są ważne dla dzieci chorych na astmę i ich matek? Ped Pol. 2005; 80: 874-9.
31. Contoli M, Barile S, Nudo E et al. Exploring quality of life and satisfaction with treatment in asthmatic patients receiving dry powder inhalers: a multinational survey. J Asthma. 2022; 59(7): 1473-83.
32. Usmani OS. New developments in inhaled drugs: within and beyond the lungs. Respiration. 2014; 88: 1-2.
33. Basheti IA, Bosnic-Anticevich SZ, Armour CL et al. Checklists for powder inhaler technique: a review and recommendations. Respir Care. 2014; 59: 1140-54.
34. Emeryk A, Janeczek K. Feedback systems in multi-dose dry powder inhalers. Adv Dermatol Allergol. 2023; 40(1): 16-21.
35. Kozma CM, Slaton TL, Monz BU et al. Development and validation of a patient satisfaction and preference questionnaire for inhalation devices. Treat Respir Med. 2005; 4(1): 41-52.
36. Ginera J, Cerrillob MV, Sierrab JA. Assessment of inhalation errors, training time and patient preference for DuoResp® Spiromax ® and Symbicort® Turbuhaler® in patients with asthma and COPD. Eur Clin Respir J. 2020; 8: 1833411.
37. Sestini P, Cappiello V, Aliani M et al. Prescription bias and factors associated with improper use of inhalers. J Aerosol Med. 2006; 19: 127-36.
38. Lavorini F. Inhaled drug delivery in the hands of the patient. J Aerosol Med Pulm Drug Deliv. 2014; 27(6): 414-8.
2. Mohan AR, Wang Q, Dhapare S et al. Advancements in the design and development of dry powder inhalers and potential implications for generic development. Pharmaceutics. 2022; 14(11): 2495.
3. Taki M, Ahmed S, Marriott C et al. The ‘stage-by-stage’ deposition of drugs from commercial single-active and combination dry powder inhaler formulations. Eur J Pharma Sci. 2011; 43: 225-35.
4. Chrystyn H, van der Palen J, Sharma R et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017; 27: 22.
5. De Boer AH, Hagedoorn P, Hoppentocht M et al. Dry powder inhalation: past, present and future. Exp Opin Drug Deliv. 2017; 14(4): 499-512.
6. Emeryk A, Emeryk-Maksymiuk J, Janeczek K et al. Inhalatory suchego proszku w dobie pandemii COVID-19 – co jest ważne dla pacjenta? Alergoprofil. 2021; 17(2): 3-9.
7. Emeryk A, Pirożyński M, Emeryk-Maksymiuk J. Dry powder inhalers – between the doctor and the patient. Adv Respir Med. 2018; 86(1): 44-52.
8. Sanders MJ. Guiding Inspiratory Flow: Development of the In-Check DIAL G16, a tool for improving inhaler technique. Pulm Med. 2017; 2017: 1495867.
9. Dal Negro WR, Turco P, Povero M. Patients’ usability of seven most used dry-powder inhalers in COPD. Multidiscip Respir Med. 2019; 14: 30.
10. Ciciliani AM, Langguth P, Wachtel P. Handling forces for the use of different inhaler devices. Int J Pharm. 2019; 560: 315-21.
11. Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019; 15: 461-72.
12. Global Strategy for Asthma Management and Prevention (GINA). Updated 2021.
13. Produkt DUEXON PRO f. Adamed Pharma S.A. Ulotka.
14. Patient decision aid inhalers for asthma. Information to help people with asthma and their healthcare professionals discuss their options for inhaler devices. NICE 2020 (access: 20.05.2022).
15. Panaszek B, Emeryk A, Bogacka E et al. Czynniki decydujące o akceptacji inhalatora suchego proszku przez chorych leczonych z powodu astmy lub POChP. Fam Med Prim. 2006; 8(3): 729-34.
16. Ninane V, Vandevoorde J, Cataldo D et al. New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences. Respir Med. 2015; 109(11): 1430-8.
17. Global Strategy for Prevention, Diagnosis and Management of COPD: 2023 Report (access: 10.01.2023).
18. Emeryk A, Janeczek K. Inhalatory suchego proszku np. G7 – najbardziej popularne inhalatory indywidualne. Alergia. 2020; 1: 11-3.
19. Dane firmy Adamed Pharma S.A. WELLNEX GmbH. Fluticasone Propionate/Salmeterol Inhalation Powder, Pre-dispensed 100/50 μg, 250/50 μg (Fluticasone propionate, Salmeterol xinafoate) Drug Product 3.2.P.2 Pharmaceutical Development.
20. Janeczek K, Emeryk A. Porównanie preparatów propionianu flutykazonu z salmeterolem dostępnych w inhalatorach dyskopodobnych oraz Dysku (doniesienie wstępne). Terapia. 2022; 8(415): 20-8.
21. Jones TL, Neville DM, Chauhan AJ. The Ellipta® in asthma and chronic obstructive pulmonary disease: device characteristics and patient acceptability. Ther Deliv. 2018; 9(3): 169-76.
22. Levy ML, Carroll W, Izquierdo Alonso JL et al. Understanding dry powder inhalers: key technical and patient preference attributes. Adv Ther. 2019; 36(10): 2547-57.
23. D’Urzo A, Chapman KR, Donohue JF et al. inhaler devices for delivery of LABA/LAMA fixed dose combinations in patients with COPD. Pulm Ther. 2019; 5: 23-41.
24. Ginera J, Cerrillob MV, Sierrab JA. Assessment of inhalation errors, training time and patient preference for DuoResp® Spiromax® and Symbicort® Turbuhaler® in patients with asthma and COPD. Eur Clin Respir J. 2020; 8: 1833411.
25. Krok E. Budowa kwestionariusza ankietowego a wyniki badań. Studia Informatica. Zeszyty Naukowe Uniwersytetu Szczecińskiego. 2015; 35: 55-73.
26. Serra-Batlles J, Plaza V, Radiola C et al. Patient perception and acceptability of multidose dry powder inhalers: a randomized crossover comparison of Diskus/Accuhaler with Turbuhaler. J Aerosol Med. 2002; 15: 59-64.
27. Van der Palen J, Klein JJ, Schildkamp AM. Comparison of a new multidose powder inhaler (Discus/Accuhaler) and the Turbuhaler regarding preference and ease of use. J Asthma. 1998; 35: 147-52.
28. Luyt D, Vermeulen J, Johanson L et al. A comparison of the ease of handling of the Diskus/Accuhaler inhaler and the Turbuhaler inhaler in children aged 6–12 years with asthma. J Aerosol Med. 1995; 8: 105-9.
29. Schlaeppi M, Edwards K, Fuller RW et al. Patient perception of the Diskus inhaler: a comparison with the Turbuhaler inhaler. Br J Clin Pract. 1996; 50: 14-9.
30. Emeryk A, Czerwińska I, Bartkowiak-Emeryk M. Jakie cechy inhalatora suchego proszku są ważne dla dzieci chorych na astmę i ich matek? Ped Pol. 2005; 80: 874-9.
31. Contoli M, Barile S, Nudo E et al. Exploring quality of life and satisfaction with treatment in asthmatic patients receiving dry powder inhalers: a multinational survey. J Asthma. 2022; 59(7): 1473-83.
32. Usmani OS. New developments in inhaled drugs: within and beyond the lungs. Respiration. 2014; 88: 1-2.
33. Basheti IA, Bosnic-Anticevich SZ, Armour CL et al. Checklists for powder inhaler technique: a review and recommendations. Respir Care. 2014; 59: 1140-54.
34. Emeryk A, Janeczek K. Feedback systems in multi-dose dry powder inhalers. Adv Dermatol Allergol. 2023; 40(1): 16-21.
35. Kozma CM, Slaton TL, Monz BU et al. Development and validation of a patient satisfaction and preference questionnaire for inhalation devices. Treat Respir Med. 2005; 4(1): 41-52.
36. Ginera J, Cerrillob MV, Sierrab JA. Assessment of inhalation errors, training time and patient preference for DuoResp® Spiromax ® and Symbicort® Turbuhaler® in patients with asthma and COPD. Eur Clin Respir J. 2020; 8: 1833411.
37. Sestini P, Cappiello V, Aliani M et al. Prescription bias and factors associated with improper use of inhalers. J Aerosol Med. 2006; 19: 127-36.
38. Lavorini F. Inhaled drug delivery in the hands of the patient. J Aerosol Med Pulm Drug Deliv. 2014; 27(6): 414-8.